Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 2/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 11/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21999456 | 0.89 | NR3C2 (0.49) | LOXL2IGF1RCCR2NR3C2CYP17A1 | |
| SCHEMBL29575346 | 0.87 | IGF1R (0.48) | IGF1RCCR2NR3C2CYP17A1ATR | |
| SCHEMBL15354529 | 0.87 | RIOK2 (0.50) | IGF1RCCR2NR3C2CYP17A1ATR | |
| SCHEMBL1940483 | 0.87 | IGF1R (0.48) | IGF1RCCR2NR3C2CYP17A1ATR | |
| SCHEMBL5780771 | 0.86 | NR3C2 (0.49) | LOXL2IGF1RCCR2NR3C2CYP17A1 | |
| SCHEMBL167992 | 0.86 | IGF1R (0.47) | IGF1RCCR2NR3C2CYP17A1ATR | |
| SCHEMBL12953977 | 0.86 | IGF1R (0.47) | IGF1RCCR2NR3C2CYP17A1ATR | |
| SCHEMBL10087555 | 0.86 | NR3C2 (0.49) | IGF1RCCR2NR3C2CYP17A1ATR | |
| SCHEMBL27483153 | 0.86 | NR3C2 (0.41) | LOXL2IGF1RCCR2NR3C2CYP17A1 | |
| SCHEMBL12277478 | 0.85 | IGF1R (0.46) | LOXL2IGF1RCCR2NR3C2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20240043384-A1 | INHIBITORS OF PU.1 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-02-08 | — | — | US | disclosed |
| WO-2022217239-A1 | INHIBITORS OF PU.1 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-13 | — | — | WO | disclosed |
| EP-1957507-B1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | IONIS PHARMACEUTICALS INC (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-1931677-B1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8673924-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673924-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586576-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1713774-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| EP-1697323-A1 | NEW 5,6-DIHYDROPYRIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | AstraZeneca AB (SE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2006052930-A1 | ANTIMICROBIAL 2-DEOXYSTREPTAMINE COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050256171-A1 | Pyrrolidine derivatives as tryptase inhibitors | ALTANA PHARMA A G (DE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005075424-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005058826-A1 | NEW 5,6-DIHYDROPYRIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | WO | disclosed |
| EP-1534267-A1 | PYRROLIDINE DERIVATIVES AS TRYPTASE INHIBITORS | ALTANA Pharma AG (DE) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004012731-A1 | PYRROLIDINE DERIVATIVES AS TRYPTASE INHIBITORS | ALTANA PHARMA AG (DE) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004012731-A1 | PYRROLIDINE DERIVATIVES AS TRYPTASE INHIBITORS | ALTANA PHARMA AG (DE) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043384-A1 | INHIBITORS OF PU.1 FOR THE TREATMENT OF DISEASE | CREBBP, JUN, SP1 | LOXL2 2401/4885IGF1R 2018/4885CCR2 422/4885 |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | LOXL2 2287/4885IGF1R 1188/4885CCR2 3721/4885 |
| US-20050256171-A1 | Pyrrolidine derivatives as tryptase inhibitors | TPSAB1, TPSB2, TPSD1 | LOXL2 2348/4885IGF1R 2973/4885CCR2 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.